Ethics and Policy in the Age of Genetics and Medicine
A presentation sponsored by the UC College of Medicine entitled Ethics and Policy in the Age of Genetics and Medicine will be given by Eric M. Meslin, PhD, director of the Indiana University Center for Bioethics, on Thursday, March 20, from 4-5 p.m. in Kresge Auditorium, UC College of Medicine Medical Sciences Building. Dr. Meslin is also a professor of medicine and molecular genetics at the Indiana University School of Medicine, and a professor of philosophy at the Indiana University School of Liberal Arts. He is also assistant dean for bioethics at the Indiana University School of Medicine.
Dr. Meslin came to Indiana University in July 2001 from the National Bioethics Advisory Commission (NBAC), where he had been executive director since 1998. NBAC was appointed by President Bill Clinton in 1995, and was charged with advising the White House and the federal government on a range of bioethics issues including cloning, stem cell research, international clinical trials, and genetic studies. Dr. Meslin received his PhD from the Bioethics Program in Philosophy at the Kennedy Institute of Ethics, Georgetown University in Washington, DC.
He has held academic positions at the University of Toronto and the University of Oxford. From 1996-98 he was program director for Bioethics Research in the Ethical, Legal, and Social Implications Research Program at the National Human Genome Research Institute in Bethesda, MD. He has been a consultant to the World Health Organization and he is co-editor of the Bioethics and Humanities Series published by Indiana University Press, and associate editor of the
Journal of Medical Ethics.
Dr. Meslin has authored or co-authored more than 75 articles and book chapters, including more than 30 publications in peer-reviewed literature, with most focusing on various topics in research ethics, clinical ethics, and health policy. This presentation is free and open to the public.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.